KRAS mutation "Novel drug TAS-102 makes headway in refractory colorectal cancer"

as reported at oncologyreport.com (main page today, "in the pipeline" section, first listed)

headed toward phase III trial


(Some might want to check out info on BINF 1120 (Avastin-like)

(medicalnewstoday.com/articles/235298.php

and Aflibercept,which much has been reported recently